Atea Pharmaceuticals, Inc. (AVIR) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
15/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseAVIR / S&P -13.57% / 15.20% |
LoseAVIR / S&P AVIR unavailable / 15.00% |
LoseAVIR / S&P 29.19% / 50.40% |
| 2026-Q12/3 |
WinAVIR / S&P 50.70% / -4.33% |
LoseAVIR / S&P AVIR unavailable / 11.30% |
WinAVIR / S&P 27.88% / 27.70% |
| 2025-Q41/3 |
WinAVIR / S&P 23.10% / 2.65% |
LoseAVIR / S&P AVIR unavailable / 9.00% |
LoseAVIR / S&P -3.00% / 13.40% |
| 2025-Q30/3 |
LoseAVIR / S&P -19.44% / 8.12% |
LoseAVIR / S&P AVIR unavailable / 4.61% |
LoseAVIR / S&P -14.49% / 13.45% |
| 2025-Q21/3 |
WinAVIR / S&P 20.40% / 10.94% |
LoseAVIR / S&P AVIR unavailable / 4.83% |
LoseAVIR / S&P -23.33% / 10.63% |
| 2025-Q10/3 |
LoseAVIR / S&P -10.75% / -4.27% |
LoseAVIR / S&P AVIR unavailable / 4.98% |
LoseAVIR / S&P -15.82% / 10.57% |
| 2024-Q41/3 |
LoseAVIR / S&P 0.00% / 2.41% |
LoseAVIR / S&P AVIR unavailable / 5.25% |
WinAVIR / S&P 21.95% / 6.15% |
| 2024-Q31/3 |
LoseAVIR / S&P 1.21% / 5.89% |
LoseAVIR / S&P AVIR unavailable / 5.89% |
WinAVIR / S&P 31.01% / 6.11% |
| 2024-Q21/3 |
LoseAVIR / S&P -18.07% / 4.28% |
LoseAVIR / S&P AVIR unavailable / 5.38% |
WinAVIR / S&P 64.06% / 5.12% |
| 2024-Q12/3 |
WinAVIR / S&P 32.46% / 10.56% |
LoseAVIR / S&P AVIR unavailable / 5.71% |
WinAVIR / S&P 48.48% / 5.59% |
| 2023-Q41/3 |
LoseAVIR / S&P 1.67% / 11.69% |
LoseAVIR / S&P AVIR unavailable / 6.81% |
WinAVIR / S&P 17.14% / 7.78% |
| 2023-Q30/3 |
LoseAVIR / S&P -19.79% / -3.27% |
LoseAVIR / S&P AVIR unavailable / 7.52% |
LoseAVIR / S&P -578.79% / -5.03% |
| 2023-Q21/3 |
WinAVIR / S&P 11.64% / 8.74% |
LoseAVIR / S&P AVIR unavailable / 9.50% |
LoseAVIR / S&P -1522.22% / -8.57% |
| 2023-Q10/3 |
LoseAVIR / S&P -30.35% / 7.50% |
LoseAVIR / S&P AVIR unavailable / 10.77% |
LoseAVIR / S&P -369.39% / -15.69% |
| 2022-Q40/3 |
LoseAVIR / S&P -15.47% / 7.56% |
LoseAVIR / S&P AVIR unavailable / 11.88% |
LoseAVIR / S&P -204.48% / -17.99% |
| 2022-Q30/3 |
LoseAVIR / S&P -19.86% / -4.88% |
LoseAVIR / S&P AVIR unavailable / 13.47% |
LoseAVIR / S&P -87.50% / -1.41% |
| 2022-Q21/3 |
WinAVIR / S&P -1.66% / -16.10% |
LoseAVIR / S&P AVIR unavailable / 13.71% |
LoseAVIR / S&P -92.74% / 11.04% |
| 2022-Q11/3 |
LoseAVIR / S&P -19.24% / -4.60% |
LoseAVIR / S&P AVIR unavailable / 15.97% |
WinAVIR / S&P 113.04% / 42.23% |
| 2021-Q40/3 |
LoseAVIR / S&P -74.50% / 11.03% |
LoseAVIR / S&P AVIR unavailable / 15.00% |
LoseAVIR / S&P -362.75% / 96.40% |
| 2021-Q31/3 |
WinAVIR / S&P 63.22% / 0.58% |
LoseAVIR / S&P AVIR unavailable / 10.77% |
LoseAVIR / S&P AVIR unavailable / 69.42% |
| 2021-Q20/3 |
LoseAVIR / S&P -65.21% / 8.55% |
LoseAVIR / S&P AVIR unavailable / 6.58% |
LoseAVIR / S&P AVIR unavailable / 51.81% |
| 2021-Q11/3 |
WinAVIR / S&P 47.80% / 6.17% |
LoseAVIR / S&P AVIR unavailable / -1.06% |
LoseAVIR / S&P AVIR unavailable / 7.39% |
| 2020-Q40/3 |
LoseAVIR / S&P AVIR unavailable / 12.15% |
LoseAVIR / S&P AVIR unavailable / -3.72% |
LoseAVIR / S&P AVIR unavailable / -33.42% |
| 2020-Q30/3 |
LoseAVIR / S&P AVIR unavailable / 8.93% |
LoseAVIR / S&P AVIR unavailable / -2.04% |
LoseAVIR / S&P AVIR unavailable / -27.10% |
| 2020-Q20/3 |
LoseAVIR / S&P AVIR unavailable / 20.54% |
LoseAVIR / S&P AVIR unavailable / -0.46% |
LoseAVIR / S&P AVIR unavailable / -27.11% |
| 2020-Q10/3 |
LoseAVIR / S&P AVIR unavailable / -19.60% |
LoseAVIR / S&P AVIR unavailable / 3.47% |
LoseAVIR / S&P AVIR unavailable / -14.75% |
| 2019-Q40/3 |
LoseAVIR / S&P AVIR unavailable / 9.07% |
LoseAVIR / S&P AVIR unavailable / 5.36% |
LoseAVIR / S&P AVIR unavailable / 2.99% |
| 2019-Q30/3 |
LoseAVIR / S&P AVIR unavailable / 1.70% |
LoseAVIR / S&P AVIR unavailable / 5.02% |
LoseAVIR / S&P AVIR unavailable / 0.21% |
| 2019-Q20/3 |
LoseAVIR / S&P AVIR unavailable / 4.30% |
LoseAVIR / S&P AVIR unavailable / 6.64% |
LoseAVIR / S&P AVIR unavailable / 8.65% |
| 2019-Q10/3 |
LoseAVIR / S&P AVIR unavailable / 13.65% |
LoseAVIR / S&P AVIR unavailable / 8.12% |
LoseAVIR / S&P AVIR unavailable / 14.29% |
| 2018-Q40/3 |
LoseAVIR / S&P AVIR unavailable / -13.52% |
LoseAVIR / S&P AVIR unavailable / 9.05% |
LoseAVIR / S&P AVIR unavailable / 18.23% |
| 2018-Q30/3 |
LoseAVIR / S&P AVIR unavailable / 7.71% |
LoseAVIR / S&P AVIR unavailable / 10.21% |
LoseAVIR / S&P AVIR unavailable / 19.06% |
| 2018-Q20/3 |
LoseAVIR / S&P AVIR unavailable / 3.43% |
LoseAVIR / S&P AVIR unavailable / 9.03% |
LoseAVIR / S&P AVIR unavailable / 14.46% |
| 2018-Q10/3 |
LoseAVIR / S&P AVIR unavailable / -0.76% |
LoseAVIR / S&P AVIR unavailable / 7.68% |
LoseAVIR / S&P AVIR unavailable / 12.46% |
| 2017-Q40/3 |
LoseAVIR / S&P AVIR unavailable / 6.64% |
LoseAVIR / S&P AVIR unavailable / 7.03% |
LoseAVIR / S&P AVIR unavailable / 13.82% |
| 2017-Q30/3 |
LoseAVIR / S&P AVIR unavailable / 4.48% |
LoseAVIR / S&P AVIR unavailable / 5.68% |
LoseAVIR / S&P AVIR unavailable / 17.57% |
| 2017-Q20/3 |
LoseAVIR / S&P AVIR unavailable / 3.09% |
LoseAVIR / S&P AVIR unavailable / 4.83% |
LoseAVIR / S&P AVIR unavailable / 17.74% |
| 2017-Q10/3 |
LoseAVIR / S&P AVIR unavailable / 6.07% |
LoseAVIR / S&P AVIR unavailable / 3.67% |
LoseAVIR / S&P AVIR unavailable / 13.32% |
| 2016-Q40/3 |
LoseAVIR / S&P AVIR unavailable / 3.82% |
LoseAVIR / S&P AVIR unavailable / 2.09% |
LoseAVIR / S&P AVIR unavailable / 7.05% |
| 2016-Q30/3 |
LoseAVIR / S&P AVIR unavailable / 3.85% |
LoseAVIR / S&P AVIR unavailable / 0.20% |
LoseAVIR / S&P AVIR unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | AVIR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 62.20% | 20.78% |
| Annualized return | 62.20% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | AVIR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -80.96% | 83.14% |
| Annualized return | -28.23% | 12.86% |
10Y · 2020-10-30 to 2026-08-27
| Metric | AVIR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -82.04% | 319.30% |
| Annualized return | -15.78% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |